

Baxter International has faced severe margin pressure and investor skepticism, but we view these challenges as temporary and see a clear path to earnings recovery.

Baxter International is a leading manufacturer and supplier of everyday hospital essentials, from IV bags and infusion pumps to smart beds and injectable drugs. The company is deeply embedded in hospital operations, with a large installed base of equipment and a broad consumables portfolio that together drive long-term customer relationships. Its core product categories are concentrated among a small number of scaled providers, which supports pricing discipline and stable margins.

Despite these strengths, Baxter's stock has fallen nearly 80% from its 2021 peak, as four temporary headwinds have weighed on margins:

- **Contract Pricing Lag:** fixed-price contracts signed before the 2021 inflation surge
- **Fluid Conservation:** reduced IV bag usage following a supply disruption
- **Stranded Costs:** overhead tied to dialysis divestiture
- **Novum IQ Pause:** temporary halt in shipments of its new large-volume infusion pump

We view these headwinds as transitory. As they abate, earnings should recover, and investor confidence is likely to return to this high-quality medtech franchise.

BAXTER TODAY


Following major divestitures, Baxter is now a simpler, more focused hospital products company. It sold its pharmaceutical contract manufacturing unit in 2023 and its dialysis business in 2025, which together accounted for roughly one third of its revenue before the separations. The result is a streamlined portfolio organized into three divisions: Medical Products & Therapies (IV solutions, infusion systems, nutrition), Healthcare Systems & Technologies (smart beds, monitoring, and connected-care equipment), and Pharmaceuticals (premix and generic injectables, anesthesia). The company's debt had swelled

	Price	Earnings Per Share			Price/Earnings		
		FY 25E	FY 26E	Normal*	FY 25E	FY 26E	Normal*
Baxter Int.	\$22.77	\$0.72	\$1.29	\$3.92	31.6x	17.7x	5.8x

Fiscal year-end December 31.
*Pzena estimate of normal earnings.
Source: S&P Capital IQ, Pzena analysis
Data as of September 30, 2025.

following its 2021 acquisition of Hillrom, but proceeds from its recent divestitures have been used to pay down borrowings, reducing net debt from \$15 billion in 2023 to \$8 billion today, with a target of around 3x net leverage by year end (Exhibit 1). A stronger balance sheet provides flexibility to reinvest for growth while navigating near-term challenges.

Exhibit 1: Net Debt and Leverage Ratio Improvement



Source: S&P Capital IQ, Company filings

CONTRACT PRICING LAG


Contracting dynamics have been the single largest drag on Baxter's margins. About 55% of the company's revenue is generated in the U.S., where most sales are governed by long-term agreements with three major group purchasing organizations (GPOs) that negotiate pricing on behalf of hospitals. Contracts signed before the 2021 inflation surge

HIGHLIGHTED HOLDING CONT.

locked in fixed prices without escalators or force-majeure protections. As supply, freight, and labor costs spiked, Baxter was unable to pass the costs through, absorbing roughly \$1 billion of incremental expenses in 2022 that reset its cost base higher and contributed to the company's decline in adjusted operating margin from 18.0% in 2020 to 13.9% in 2024.

The cycle is now turning in Baxter's favor. Two of the three major GPO agreements reset in early 2025, with the final renewal scheduled for 2026. The new contracts incorporate greater flexibility to pass through inflationary costs, protecting margins from future cost volatility. As these agreements reset to reflect today's cost base, margins should begin to recover, representing a major step toward normal operating margins of roughly 20% over time (Exhibit 2).

Exhibit 2: Path to Normal Margin



Source: Company filings, Pzena projections

FLUID CONSERVATION

In late 2024, Hurricane Helene flooded Baxter's North Cove facility in North Carolina—its largest IV solutions manufacturing plant and the source of approximately

60% of the U.S. IV fluid supply—forcing a temporary shutdown and prompting hospitals to conserve fluids. Hospitals used fewer IV bags per patient, delayed some non-urgent procedures, and switched to direct drug injections instead of IV infusions. Even after supply returned, cautious practices have lingered, leaving IV-solution volumes approximately 20% below historical levels. Because IV fluids are low-value, high-volume products, where scale is critical to profitability, this underutilization has weighed on margins and contributed to recent share weakness.

The situation closely resembles the aftermath of Hurricane Maria in 2017, which severely disrupted Baxter's Puerto Rico IV fluid facilities and caused a nationwide shortage of IV bags. Hospitals similarly cut back on fluid usage, and management overestimated how quickly demand would return. In that case, volumes eventually recovered as supply stability was re-established, and the same gradual normalization appears to be underway today. The impact of IV fluid normalization is difficult to quantify separately from that of contract repricing, but together they are expected to contribute roughly 230 basis points of margin uplift (Exhibit 2).

STRANDED COSTS

As part of the dialysis divestiture (now Vantive), Baxter agreed to continue providing certain back-office services and to manufacture select products on Vantive's behalf for a limited period, as is customary in such separations. In 2025, these transition service and manufacturing agreements represent roughly \$500 million of combined activity and are dilutive to operating margins.

As these agreements expire and production winds down through 2027, Baxter will eliminate stranded overhead and exit low-return activity, contributing roughly 250 basis points of margin uplift, which is the biggest source of recovery ahead. Additionally, the dialysis business itself was structurally dilutive, earning roughly half the returns on invested capital

HIGHLIGHTED HOLDING CONT.

of Baxter's continuing operations; therefore, its separation raises the company's underlying margin profile. This mix improvement helps explain why our normalized margin forecast of roughly 20% sits above Baxter's historical range, reflecting a structurally higher-margin portfolio.

NOVUM IQ PAUSE

The Novum IQ Large Volume Pump is Baxter's next-generation infusion platform, designed to deliver IV fluids in a controlled, automated manner. In mid-2025, Baxter voluntarily paused new shipments and installations after identifying workflow issues in certain intensive-care settings and implemented corrective actions. Installed units remain in service, but the pause has raised concern for a product intended to anchor Baxter's next phase of growth. The pause occurred after the second quarter and therefore has not yet been reflected in reported results, although investors have already priced in the rollout's disruption. Financially, exposure is limited: Novum IQ represents roughly 2% of revenue, and high-margin consumables used across both Novum IQ and the legacy Spectrum pump continue to ship.

Investor concern reflects both the near-term earnings impact and questions around credibility. The platform was meant to demonstrate Baxter's ability to modernize its infusion systems and reassert leadership in a concentrated market where reliability and hospital trust are paramount. The pause interrupts that momentum and introduces uncertainty around the timing of a broader launch. Because the issues identified to date are primarily related to software and workflow, rather than structural hardware defects, corrective actions should allow shipments to resume once validations are complete, allowing the platform to regain traction as a growth driver for Baxter.

CONCLUSION

All four of Baxter's headwinds are company-specific and temporary, with resolutions underway. Risks remain as these areas normalize: pricing resets could lag, volume recovery could take longer, stranded costs could run higher, or the Novum IQ relaunch could face further delay. However, these issues are executional and largely within management's control. Broader pressures, including tariff uncertainty and weak sentiment across healthcare, have also weighed on the stock, despite limited impact on fundamentals. At today's valuation, the market is treating these temporary issues as permanent, pricing Baxter at only 5.8x our estimate of normalized earnings of \$3.92 per share.

For long-term investors, this pessimism, in our opinion, creates opportunity. Baxter's franchise centers on essential, nondiscretionary hospital products, where demand is steady, scale advantages persist, and recurring consumables reinforce long-term customer relationships. Hospitals rarely switch suppliers, while aging populations and chronic disease sustain growth. This durability provides a strong foundation for margins to expand and for earnings to normalize, setting up a powerful recovery as temporary pressures fade.

FURTHER INFORMATION

These materials are intended solely for informational purposes. The views expressed reflect the current views of Pzena Investment Management (“PIM”) as of the date hereof and are subject to change. PIM is a registered investment adviser registered with the United States Securities and Exchange Commission. PIM does not undertake to advise you of any changes in the views expressed herein. There is no guarantee that any projection, forecast, or opinion in this material will be realized. Past performance is not indicative of future results.

All investments involve risk, including loss of principal. Investments may be in a variety of currencies and therefore changes in rates of exchange between currencies may cause the value of investments to decrease or increase. The price of equity securities may rise or fall because of economic or political changes or changes in a company’s financial condition, sometimes rapidly or unpredictably. Investments in foreign securities involve political, economic and currency risks, greater volatility and differences in accounting methods. These risks are greater for investments in Emerging Markets. Investments in small-cap or mid-cap companies involve additional risks such as limited liquidity and greater volatility than larger companies. PIM’s strategies emphasize a “value” style of investing, which targets undervalued companies with characteristics for improved valuations. This style of investing is subject to the risk that the valuations never improve or that returns on “value” securities may not move in tandem with the returns on other styles of investing or the stock market in general.

This document does not constitute a current or past recommendation, an offer, or solicitation of an offer to purchase any securities or provide investment advisory services and should not be construed as such. The information contained herein is general in nature and does not constitute legal, tax, or investment advice. PIM does not make any warranty, express or implied, as to the information’s accuracy or completeness. Prospective investors are encouraged to consult their own professional advisers as to the implications of making an investment in any securities or investment advisory services.

The specific portfolio securities discussed in this presentation are included for illustrative purposes only and were selected based on their ability to help you better understand our investment process. They were selected from securities in one or more of our strategies and were not selected based on performance. PIM is a discretionary investment manager and does not make “recommendations” to buy or sell any securities. There is no assurance that any securities discussed herein remain in our portfolios at the time you receive this presentation or that securities sold have not been repurchased.

Baxter International was held in our Global Value, Large Cap Value, Large Cap Focused Value, Focused Value, Mid Cap Focused Value, and other strategies during the third quarter of 2025.

For EU Investors Only:

This marketing communication is issued by Pzena Investment Management Europe Limited (“PIM Europe”). PIM Europe (No. C457984) is authorised and regulated by the Central Bank of Ireland as a UCITS management company (pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011, as amended), with additional authorisation for management of portfolios of investments, in accordance with mandates given by investors on a discretionary, client-by-client basis, where such portfolios include one or more of the investment instruments listed in Section C of the Annex to the MiFID (Markets in Financial Instruments) Regulations 2017 (S.I. No. 375 of 2017), as amended), and investment advice concerning one or more of the instruments listed in Annex I, Section C to Directive 2004/39/EC. PIM Europe is registered in Ireland with the Companies Registration Office (No. 699811), with its registered office at Riverside One, Sir John Rogerson’s Quay, Dublin, 2, Ireland. Past performance is not indicative of future results. The value of your investment may go down as well as up, and you may not receive upon redemption the full amount of your original investment. The views and statements contained herein are those of Pzena Investment Management and are based on internal research.

For Australia and New Zealand Investors Only:

This document has been prepared and issued by Pzena Investment Management, LLC (ARBN 108 743 415), a limited liability company (“Pzena”). Pzena is regulated by the Securities and Exchange Commission (SEC) under U.S. laws, which differ from Australian laws. Pzena is exempt from the requirement to hold an Australian financial services license in Australia in accordance with ASIC Class Order CO 03/1100 and the transitional relief under ASIC Corporations (Repeal and Transitional) Instrument 2016/396, extended through 31 March 2026 by ASIC Corporations (Amendment) Instrument 2024/497. Pzena offers financial services in Australia to ‘wholesale clients’ only pursuant to that exemption. This document is not intended to be distributed or passed on, directly or indirectly, to any other class of persons in Australia.

In New Zealand, any offer is limited to ‘wholesale investors’ within the meaning of clause 3(2) of Schedule 1 of the Financial Markets Conduct Act 2013 (‘FMCA’). This document is not to be treated as an offer, and is not capable of acceptance by, any person in New Zealand who is not a Wholesale Investor.

For South African Investors Only:

The Pzena Emerging Markets Focused Value Fund, Pzena Emerging Markets Select Value Fund, Pzena Global Focused Value Fund, Pzena Global Value Fund are registered and approved under section 65 of CISCA.

Collective Investment Schemes in Securities (CIS) should be considered as medium- to long-term investments. The value may go up as well as down and past performance is not necessarily a guide to future performance. CISs are traded at the ruling price and can engage in scrip lending and borrowing. A schedule of fees, charges and maximum commissions is available on request from the Manager. A CIS may be closed to new investors in order for it to be managed more efficiently in accordance with its mandate. There is no guarantee in respect of capital or returns in a portfolio. Representative Office: Prescient Management Company (RF) (Pty) Ltd is registered and approved under the Collective Investment Schemes Control Act (No.45 of 2002). For any additional information such as fund prices, fees, brochures, minimum disclosure documents and application forms please go to www.pzena.com.